Loading
Latest filing published 22 May 2023 for RVL Pharmaceuticals plc, €4,398.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Christopher Klein is a declared insider of RVL Pharmaceuticals plc (board member), with filings sourced from SEC (Form 4). Over a trading history stretching from 24 January 2019 to 18 May 2023, the count stands at 9 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
On 22 May 2023 came the latest disclosure, a share grant for €4,398 in RVL Pharmaceuticals plc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations